The Drug Provisions within the Inflation Reduction Act (IRA) of 2022 are of critical importance to pharmaceutical manufacturers, who now have a host of new considerations when thinking through their portfolio strategies and pricing and market access considerations. In this episode of TrialCard TALK, Landy and Eric welcome to the studio two experts on the topic: Megan Thomas, Partner, Triangle Insights Group and Jason Zemcik, Principal Consultant for Policy Reporter.